

## ASX Announcement

### Imugene's onCARlytics to be showcased in three abstracts at SITC Annual Meeting

---

**Sydney, Australia, 6 October 2022:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce that its onCARlytics (CF33-CD19) oncolytic virus technology will be featured in three abstracts at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC), to be held in Boston, USA on 8-12 November 2022.

Known as one of the most prestigious immunotherapy events on the calendar, SITC 2022 will feature cutting-edge research presentations by various experts, oral, and poster abstract presentations and various opportunities for networking and discussion with members of the oncology community.

The abstract titles were released at 8am EDT (US Eastern Daylight Time) 5 October 2022, with those featuring Imugene's onCARlytics as follows:

Title: **Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors**

Abstract #: 305

Title: **CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis® CD19 T cells results in significant tumor killing**

Abstract #: 368

Title: **CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de novo CD19+ solid tumors**

Abstract #: 847

Imugene will announce further detail from these abstracts at the time of the event.

onCARlytics is a CD19-expressing oncolytic virus that enters tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19 targeting therapies. Imugene exclusively



licensed the technology from City of Hope, one of the largest cancer research and treatment organisations in the US.

For more about SITC 2022, please visit: <https://www.sitcancer.org/2022/home>

For more information please contact:

**Leslie Chong**

**Managing Director and Chief Executive Officer**

[info@imugene.com](mailto:info@imugene.com)

**Investor Enquiries**

[investor@imugene.com](mailto:investor@imugene.com)

**Media Enquiries**

Matt Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

View us on YouTube @Imugene Limited

### **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-



reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immunology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer*

*Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*

For personal use only